VitaNova Life Sciences Corporation VNOV
OTC PK
| 07/31/2026 | 04/30/2026 | 01/31/2026 | 10/31/2025 | 07/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 209.53% | -8.62% | 130.17% | 46.22% | -4.24% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 209.53% | -8.62% | 130.17% | 46.22% | -4.24% |
| Cost of Revenue | 729.34% | 91.03% | 230.50% | 22.01% | -0.57% |
| Gross Profit | -55.67% | -77.13% | 67.09% | 67.39% | -6.01% |
| SG&A Expenses | 50.89% | 398.67% | 235.32% | 73.39% | -14.67% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 225.53% | 117.57% | 232.45% | 42.88% | -11.44% |
| Operating Income | -277.16% | -110.15% | -57.12% | 58.47% | 28.63% |
| Income Before Tax | -277.16% | -109.90% | -56.88% | 63.32% | 28.63% |
| Income Tax Expenses | -93.53% | -144.40% | 158.07% | 125.98% | 41.84% |
| Earnings from Continuing Operations | -165.87% | -97.81% | -160.82% | 9.82% | 16.12% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -165.87% | -97.81% | -160.82% | 9.82% | 16.12% |
| EBIT | -277.16% | -110.15% | -57.12% | 58.47% | 28.63% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -164.29% | -97.81% | -160.23% | 10.26% | 15.15% |
| Normalized Basic EPS | -283.33% | -109.88% | -56.79% | 60.87% | 29.41% |
| EPS Diluted | -164.29% | -97.81% | -160.23% | 10.26% | 15.15% |
| Normalized Diluted EPS | -283.33% | -109.88% | -56.79% | 60.87% | 29.41% |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |